References

1. Andén, N.-E., Roos, B.-E., Werdinius, B.: The occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. *Life Sci.* **2**, 448—458 (1963).
2. Bowers, M. B., Jr.: CSF Homovanillic acid: Effects of probenecid and α -methyl tyrosine. *Life Sci.* **9**, 691—694 (1970).
3. Bunney, W. E., Jr., Brodie, K. E., Murphy, D. L., Goodwin, R. K.: Studies of alpha-methyl-paratyrosine, L-dopa, and L-tryptophan in depression and mania. *Amer. J. Psychiat.* **127**, 872—881 (1971).
4. Engelman, K., Horwitz, D., Jéquier, E., Sjoerdsma, A.: Biochemical and pharmacologic effects of α -methyltyrosine in man. *J. clin. Invest.* **47**, 577—594 (1968).
5. Gershon, S., Hekimian, L. J., Floyd, A., Hollister, L. E.: AMT in schizophrenia. *Psychopharmacologia (Berl.)* **11**, 189 (1967).
6. Guldberg, H. C.: Changes in amine metabolite concentrations in cerebrospinal fluid as an index of turnover. In: *Metabolism of amines in the brain. Ed.: G. Hooper.* London: Macmillan 1969.
7. — Ashcroft, G. W., Crawford, T. B. B.: Concentrations of 5-HIAA and HVA in the cerebrospinal fluid of the dog before and during treatment with probenecid. *Life Sci.* **5**, 1571—1575 (1966).
8. Jönsson, L.-E., Gunne, L.-M., Ånggård, E.: Effects of alpha-methyltyrosine in amphetamine-dependent subjects. *Pharmacol. Clin.* **2**, 27—29 (1969).
9. Neff, N. H., Tozer, T. N., Brodie, B. B.: A specialized transport system to transfer 5-HIAA directly from brain to blood. *Pharmacologist* **6**, 162 (1964).
10. Roos, B.-E.: Metabolites of the monoamines in the cerebrospinal fluid. Symposium at Bel. Air, Geneva 1970.
11. — Sjöström, R.: 5-HIAA (and HVA) levels in the cerebrospinal fluid after probenecid application in patients with manic-depressive psychosis. *Pharmacol. Clin.* **1**, 153—155 (1969).
12. Sharman, D. R.: The significance of pharmacologically active amines in animal tissues and body fluids. Edinburgh: Thesis 1960.
13. Spector, S., Sjoerdsma, A., Udenfriend, S.: Blockade of endogenous nor-epinephrine synthesis by α -methyl-tyrosine, and inhibitor of tyrosine hydroxylase. *J. Pharmacol. exp. Ther.* **147**, 86—95 (1965).

Dr. Rolf Sjöström

Psychiatric Research Center, Ulleråker Hospital
University of Uppsala, S-750 17 Uppsala, Sweden

Erratum

Alpha-Methylparatyrosine and Sleep in the Rat

E. HARTMANN, T. J. BRIDWELL, and J. J. SCHILDKRAUT

Psychopharmacologia **21**, 157—164 (1971)

Received September 9, 1971

Throughout the paper, the drug used was dl-alpha-methylparatyrosine, *not* l-alpha-methylparatyrosine.

Ernest Hartmann, M. D.

The Commonwealth of Massachusetts

Department of Mental Health, Boston State Hospital
Boston, Massachusetts 02124, U.S.A.